Form 4: Neurocrine Biosciences Chief Regulatory Officer Reports Stock Transactions
SEC Form 4 Filing
Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership.
- The report includes transactions on February 13, 2025, involving the acquisition and disposal of common stock and restricted stock units.
- Delaet acquired 34,153 stock options at a price of $117.18 on February 12, 2025.
- She also acquired 6,401 restricted stock units on February 12, 2025.
- Sales of common stock were executed under Rule 10b5-1 trading plans adopted on March 15, 2023, and June 14, 2024.
- The weighted average sales prices for common stock ranged from $115.98 to $117.75.
- Following the reported transactions, Delaet directly owns 4,730 shares of common stock.
- She also holds derivative securities including 34,153 stock options, 2,718 restricted stock units granted in 2023, and 4,203 restricted stock units granted in 2024.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine transactions under pre-existing trading plans, indicating no significant positive or negative implications.
Positives
- The acquisition of stock options and restricted stock units demonstrates Delaet's continued investment in Neurocrine Biosciences.
- The use of Rule 10b5-1 trading plans suggests a structured and transparent approach to stock sales.
Future Outlook
The restricted stock units will continue to vest annually through February 12, 2029, and the stock options expire on February 12, 2035.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Comparing Delaet's transactions to those of other Chief Regulatory Officers in similar-sized biotech companies could provide context.
- Analyzing the vesting schedules of her restricted stock units against industry norms for executive compensation packages would be useful.
- Comparing the adoption and execution of her 10b5-1 trading plans to those of executives at companies like Amgen or Biogen could offer insights into best practices.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding insider trading activity.
- The vesting of restricted stock units incentivizes the officer to remain with the company and contribute to its long-term success.
Key Dates
| Date | Description |
|---|---|
| March 15, 2023 | Date of adoption of Rule 10b5-1 trading plan. |
| February 13, 2023 | Date of grant for 1,358 Restricted Stock Units. |
| June 14, 2024 | Date of adoption of Rule 10b5-1 trading plan. |
| February 13, 2024 | Date of grant for 1,401 Restricted Stock Units. |
| February 12, 2025 | Date of stock option and restricted stock unit acquisition. |
| February 13, 2025 | Date of common stock transactions. |
| February 12, 2026 | Date of vesting for 1/4 of the Restricted Stock Units. |
| February 13, 2026 | Date of vesting for 1,359 shares of Restricted Stock Units. |
| February 12, 2027 | Date of vesting for 1/4 of the Restricted Stock Units. |
| February 13, 2027 | Date of vesting for 1,401 shares of Restricted Stock Units. |
| February 12, 2028 | Date of vesting for 1/4 of the Restricted Stock Units. |
| February 13, 2028 | Date of vesting for 1,401 shares of Restricted Stock Units. |
| February 12, 2029 | Date of vesting for 1/4 of the Restricted Stock Units. |
| February 12, 2035 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.